Inside a New Orleans convention center this June, researchers presented findings that could reshape how nearly 37 million Americans manage type 2 diabetes—and the evidence hinges on a small, wearable device that tracks glucose in real time. Tamara Oser, M.D., from the University of Colorado Anschutz, and her team found that continuous glucose monitoring (CGM) delivers measurable, clinically meaningful improvements for adults with type 2 diabetes who aren't on insulin, challenging the assumption that CGM's benefits apply mainly to those injecting insulin daily.
The study speaks to a fundamental gap in diabetes care. Most people with type 2 diabetes manage their condition with oral medications and lifestyle changes, yet CGM technology has historically been reserved for insulin users. This research, presented at the American Diabetes Association's annual meeting, changes that calculus. Oser's team randomly assigned 283 adults with type 2 diabetes and HbA1c levels of 7.5% or higher to either a Dexcom G7 CGM device or routine care for 26 weeks. The results were striking: participants using CGM achieved a 0.9% greater reduction in HbA1c—a key marker of long-term blood sugar control—compared to those receiving standard care. For context, such a reduction substantially lowers the risk of diabetes-related complications like kidney disease, nerve damage, and vision loss.
The benefits extended beyond the numbers on a lab report. CGM users spent five additional hours per day within the glucose target range of 70 to 180 mg/dL, the sweet spot for healthy blood sugar management. This shift matters because time spent outside that range, whether too high or too low, compounds damage over months and years. Equally significant, participants in the CGM group reported greater satisfaction with glucose monitoring and measurably reduced diabetes-related distress—a reality that captures something clinical trials often miss: the psychological burden of managing a chronic disease.
The study population mirrored real-world diversity. Forty percent of participants were using incretin mimetics, and 37% were on sodium-glucose cotransporter 2 inhibitors (SGLT2i), two common medication classes for type 2 diabetes. Others relied on neither. Among those not on these medications, baseline HbA1c averaged 9.0%, indicating more severe hyperglycemia, yet CGM still delivered meaningful improvement across all subgroups. This consistency suggests the technology's value isn't limited to a narrow patient profile.
Thomas W. Martens, M.D., from Park Nicollet Clinic in Minneapolis and a coauthor of the research, framed the implications plainly: "These findings can help reshape diabetes management and expand treatment options for patients, improve glucose levels and A1C management for clinicians, and ultimately reduce diabetes-related complications." The statement underscores what's at stake—not just better numbers, but fewer hospitalizations, fewer amputations, fewer preventable deaths.
The findings arrive at a moment when diabetes management is increasingly data-driven, yet access to continuous glucose monitoring remains uneven across income levels and insurance coverage. This research provides clinicians with evidence they need to advocate for broader CGM access. For the millions of type 2 diabetes patients navigating daily management with oral medications, the message is hopeful: technology designed to illuminate glucose patterns isn't just for insulin users anymore.